Business Context and Reporting Period
SIGA Technologies, Inc. filed this Form 8-K on September 7, 2021, reporting a material event under Item 8.01 Other Events. The company is a Delaware corporation with its principal executive offices in New York, New York, and its common stock trades on The Nasdaq Global Market under the symbol SIGA.
Key Financial Metrics
This filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed relates to a contract value:
- Contract Value: Approximately $112.5 million for the delivery of oral TPOXX courses.
Material Changes
The primary material change reported is the exercise of a procurement option by the U.S. Government under the 19C Biomedical Advanced Research and Development Authority (BARDA) contract. This action secures the delivery of approximately $112.5 million worth of product.
Guidance, Outlook, and Management Commentary
Management indicated that product deliveries associated with this option exercise are targeted for the 2021 calendar year. The filing notes that this option exercise was also disclosed in the Federal Procurement Data System. No other guidance, risks, or contingencies were detailed in this specific report.
Investor Verification Checklist
- Verify the total value of the BARDA contract and the cumulative amount of options previously exercised.
- Confirm the specific delivery schedule and milestones for the $112.5 million order within 2021.
- Review the Federal Procurement Data System for additional details on the contract terms.
- Assess the impact of this order on the company's revenue recognition timeline and cash flow projections.